Therapeutic implications of the TGF-β system

This publication has 48 references indexed in Scilit:

• Transforming growth factor-beta (TGFβ) is chemotactic for human monocytes and induces their expression of angiogenic activity
  Published by Elsevier ,2005
• Increase of Plasma Transforming Growth Factor Beta (TGFβ) During Immunotherapy with IL-2
  Cancer Investigation, 1995
• The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-β1 in metastatic human breast cancer: an immunocytochemical study
  European Journal Of Cancer, 1994
• Recombinant transforming growth factor beta 1 and beta 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin.
  The Journal of Experimental Medicine, 1994
• Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
  Journal of Clinical Investigation, 1993
• Regulation of the levels of three transforming growth factor β mRNAs by estrogen and their effects on the proliferation of human breast cancer cells
  Molecular and Cellular Endocrinology, 1993
• Mitotic activity, apoptosis and TRPM‐2 mRNA expression in dmba‐induced rat mammary carcinoma treated with anti‐estrogen toremifene
  International Journal of Cancer, 1993
• Apoptosis in Toremifene-Induced Growth Inhibition of Human Breast Cancer Cells In Vivo and In Vitro
  JNCI Journal of the National Cancer Institute, 1993
• Potentiation of Metastatic Capacity by Transforming Growth Factor‐β1 Gene Transfection
  Japanese Journal of Cancer Research, 1993
• Transforming growth factor β1 is implicated in the failure of tamoxifen therapy in human breast cancer
  British Journal of Cancer, 1991